Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Other financing activities (2023 - 2025)

BioXcel Therapeutics (BTAI) has 3 years of Other financing activities data on record, last reported at $686000.0 in Q3 2025.

  • For Q3 2025, Other financing activities rose 4800.0% year-over-year to $686000.0; the TTM value through Sep 2025 reached $1.7 million, up 723.15%, while the annual FY2024 figure was $474000.0, 41.55% down from the prior year.
  • Other financing activities reached $686000.0 in Q3 2025 per BTAI's latest filing, up from $3000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $803000.0 in Q1 2025 and bottomed at $3000.0 in Q2 2025.
  • Average Other financing activities over 3 years is $326625.0, with a median of $148000.0 recorded in 2024.
  • Peak YoY movement for Other financing activities: plummeted 84.17% in 2024, then soared 4800.0% in 2025.
  • A 3-year view of Other financing activities shows it stood at $72000.0 in 2023, then soared by 148.61% to $179000.0 in 2024, then skyrocketed by 283.24% to $686000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $686000.0 in Q3 2025, $3000.0 in Q2 2025, and $803000.0 in Q1 2025.